Amgen

Amgen is a leading biotechnology company focused on transforming new ideas and discoveries into medicines for patients with serious illnesses. Established in 1980, the company specializes in providing investments in the healthcare and bio-tech sectors across North America. Amgen offers products for the treatment of illnesses in various areas including oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company is deeply rooted in science and innovation, with a commitment to developing novel products and delivering innovative human therapeutics to address serious diseases. Amgen has a global presence, with locations in Australia and Hong Kong, focusing on biologics and the development of cutting-edge therapies.

Suzanne Blaug

SVP, Global Marketing and Commercial Development

Robert Bradway

Chairman and CEO

David W. Meline

EVP and CFO

Cynthia M. Patton

SVP and Chief Compliance Officer

David Piacquad

SVP

45 past transactions

Laboratorio Quimico Farmaceutico Bergamo

Acquisition in 2011
Laboratorio Quimico Farmaceutico Bergamo is operates as a pharmaceutical company.

Darmiyan

Non Equity Assistance in 2017
Darmiyan, Inc. develops a commercial diagnostic software platform for the early detection, monitoring, and stratification of Alzheimer’s disease and other neurodegenerative. It offers BrainSee, a Software as a Service (SaaS) platform that analyzes the scans and provides detailed brain maps with quantification of neurodegeneration in each voxel, as well as a summary score that reflects the person’s brain health and the likelihood of future cognitive decline. The company’s BrainSee is a virtual microscope of the human brain that takes standard clinical brain MRI and basic cognitive tests and generates brain maps and scores that indicate pathology at the earliest stages of the disease when treatments are feasible. The company was founded in 2014 and is based in San Francisco, California.

Otezla

Acquisition in 2019
Otezla® is a prescription medicine approved for the treatment of patients with moderate
Keck Graduate Institute (KGI) is part of the prestigious Claremont college system, in Claremont, California. Keck is one of the few graduate schools exclusively dedicated to the study of biosciences. The school’s graduate programs blend academics with business-oriented approaches to the field. KGI awards master’s degrees, certificates and post-doctoral degrees in Biosciences and Biosciences Management. The school also offers degrees in Applied Life Sciences. Students receive a comprehensive education that integrates science, technology and management skills. Learning methods are also comprehensive and include scientific research and mentorship from outside professionals. Visiting mentors work in various capacities within the biosciences industry. This diverse education leads to diverse employment among graduates. Some of the areas in which graduates work include: * Medical diagnostics * Market research * Food technology * Medical writing * Pharmaceutical sales * Vaccine research * Biofuels development Admissions requirements include submission of transcripts, a resume, an essay, a personal statement and lists of references. Applicants are encouraged to apply for tuition fellowships, which can cover up to a substantial amount of KGI’s tuition. Students may also apply for federal loans. Federal loans require the FAFSA, while fellowships require a separate application. Keck Graduate Institute also honors the GI Bill, through which veterans may receive a tuition waiver.

Ilypsa

Acquisition in 2007
It discovers and develops renal care pharmaceutical products. It develops non-absorbed polymeric phosphate and potassium binder compounds to treat chronic kidney diseases. The company, formerly known as Symyx Therapeutics, Inc. was founded in 2002 and is based in Santa Clara, California.

GlaxoSmithKline plc, All Product Rights To Prolia, XGEVA And Vectibix

Merger/Acquisition in 2015
As of 2015, all product rights to Prolia, XGEVA And Vectibix of GlaxoSmithKline plc were acquired by Amgen Inc. GlaxoSmithKline plc, All Product Rights To Prolia, XGEVA And Vectibix comprises the remaining rights of three pharmaceutical products namely Prolia (denosumab), XGEVA (denosumab) and Vectibix (panitumumab) in 48 countries.

Synergen

Acquisition in 1994
Synergen offers revenue cycle management optimization solutions, consulting services and analytics to the healthcare industry. It utilizes technology, analytics, and expertise to help partners maximize and realize their organization’s full revenue potential. The company is driven by a mission to achieve quality outcomes with high economic value. Since its foundation, Synergen has grown exponentially while adding value to its clients. It has expanded its expertise to diverse specialties and large enterprise clients in revenue cycle management and analytics. Synergen was founded in 2011 and is headquartered in Dallas, Texas.

Neumora Therapeutics

Corporate Round in 2021
Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Avidia

Acquisition in 2006
Avidia, Inc., a biopharmaceutical company, engages in discovering and developing therapeutic proteins. The company offers Avimer therapeutic proteins, which are used to address various therapeutic areas, including autoimmunity, inflammation, oncology, and neurology. Avidia, Inc. was founded in 2003 and is headquartered in Mountain View, California.

Catherex

Acquisition in 2015
In April 2010, Medigene assigned its development program of oncolytic (cancer-killing) herpes simplex viruses (oHSV), to Catherex, Inc.

DeCODE Genetics

Acquisition in 2012
DeCODE Genetics is a biopharmaceutical company that develops and offers diagnostic tests for variants in genes. DeCODE was established to identify human genes associated with common diseases using population studies, and apply the knowledge gained to guide the development of candidate drugs. The company has discovered key genetic risk factors for many common diseases ranging from cardiovascular disease to cancer. DeCODE Genetics was founded in 1996 and is based in Reykjavik, Iceland.

Tularik

Acquisition in 2004
Tularik engages in the discovery and development of orally available medicines that act through the regulation of gene expression. The company is considered a pioneer in the field of cell signaling and the control of gene expression. The company is focused primarily of three main areas; inflammation, metabolic diseases and oncology. Tularik was founded by David Goeddel along with Steve McKnight and Robert Tjian in 1991. The company was acquired by Amgen for US$ 1.3 billion in 2004.

Science 37

Venture Round in 2020
Science 37 is making the promise of virtual trials the new reality. By engaging with patients from the comfort of their own home, the company provides access to patients who can never be reached by traditional site-based research models. Its virtual model has proven to enroll faster, retain patients at a higher rate, and reach a more representative patient population. Science 37 has conducted more virtual (or decentralized), interventional trials than any other company, using an expansive, in-house network of telemedicine investigators and home-health nurses. The company's research is powered by the industry’s most comprehensive, fully integrated clinical trial platform purpose-built to conduct virtual trials.

Catherex, Inc.

Merger/Acquisition in 2015
As of December 31, 2015, Catherex, Inc. was acquired by Amgen Inc.. Catherex, Inc. intends to develop Oncolytic Herpes Simplex Viruses program used for the treatment of cancer. The company is based in Philadelphia, Pennsylvania.

Oxford Nanopore Technologies

Merger/Acquisition in 2018
Oxford Nanopore Technologies Limited develops and commercializes nanopore-based electronic systems for analysis of single molecules. The company offers MinION, a portable device for molecular analysis based on nanopore technology and is adaptable for the analysis of DNA, RNA, proteins, and small molecules; MinIT, an analysis and device control accessory for nanopore DNA sequencing; PromethION, a tablet-sized benchtop instrument that provides real-time data streaming; GridION system for molecular sensing applications; 109 cDNA Kits for its real-time and scalable sequencing technology that provides high throughput whilst generating complete sequences of full-length cDNA strands; and Flongle, a paradigm of smaller on-demand DNA or RNA sequencing tests with the potential to transform a range of applications where insights are required at low cost. Its devices are used in scientific research, personalized medicine, crop science, and security and defense applications. The company sells its products online. Oxford Nanopore Technologies Limited was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies Limited in May 2008. The company was incorporated in 2005 and is based in Oxford, United Kingdom with additional offices in the United Kingdom, the United States, China, Japan, Germany, France, India, and Singapore.

Dezima Pharma B.V.

Merger/Acquisition in 2015
Dezima Pharma B.V. develops protein-based compounds for treatment of cardiovascular disease related to dyslipidemia. The company was founded in 2012 and is based in Naarden, the Netherlands. As of October 14, 2015, Dezima Pharma B.V. operates as a subsidiary of Amgen Inc..

Dezima Pharma

Acquisition in 2015
Dezima Pharma B.V. develops protein-based compounds for treatment of cardiovascular disease related to dyslipidemia. The company was founded in 2012 and is based in Naarden, the Netherlands.

Immatics US

Series E in 2017
Immatics US Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient, where they recognize and kill tumor cells. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company has a strategic cancer immunotherapy collaboration with Roche to research, develop, and commercialize various new cancer peptide antigen-based immunotherapies for targeting primarily gastric, prostate, and non-small cell lung cancer. Immatics US Inc. was founded in 2015 and is headquartered in Houston, Texas. Immatics US Inc. operates as a subsidiary of immatics biotechnologies GmbH.

Celimmune LLC

Merger/Acquisition in 2018
Celimmune LLC, a clinical development-stage immunotherapy company, engages in treating and preventing immune mediated diseases. The company is based in Lebanon, New Jersey. As of November 30, 2017, Celimmune LLC operates as a subsidiary of Amgen Inc.

MN Pharmaceuticals

Acquisition in 2012
MN is the leading supplier of pharmaceuticals to hospitals in Turkey and garnered sales of about $200 million last year, according to the statement. It was the first Turkish pharmaceutical company to win a license from the Food and Drug Administration to sell products in the U.S.

SiteOne, Inc.

Series B in 2017
SiteOne Therapeutics is a San Francisco-based company that develops novel therapeutics and diagnostics. They develop products safely, effectively, and efficiently treat acute and chronic pain without the limitations of existing therapies, such as NSAIDs and opioids. Their lead therapeutic candidates are highly selective inhibitors of a voltage-gated sodium ion channel, Naᵥ1.7, which plays a critical role in the generation and conduction of pain signals.

CancerVax

Acquisition in 2012
Micromet is a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer. Their lead product candidate, Canvaxin, is one of a new class of products being developed in the area of specific active immunotherapy, also known as therapeutic cancer vaccines.

Amgen K.K.

Merger/Acquisition in 2020
Amgen Astellas Biopharma K.K. develops, manufactures, and sells pharmaceutical products. The company was founded in 2013 and is based in Chiyoda, Japan. Amgen K.K. was formerly known as Amgen Astellas Biopharma K.K.. As a result of acquisition of Amgen Astellas Biopharma K.K..by Amgen Inc., Amgen Astellas Biopharma K.K.'s name was changed. Amgen K.K. operates as a subsidiary of Amgen Inc.

Abgenix

Acquisition in 2005
Abgenix is a biopharmaceutical company engaged in the discovery, development, and manufacture of human therapeutic antibodies for the treatment of various disease conditions such as cancer, inflammation, and metabolic disease. Its antibody therapeutic product candidates, which are in clinical trials include Panitumumab (ABX-EGF), a human antibody therapeutic product candidate directed against the epidermal growth factor receptor and a candidate for the treatment of various solid tumors.  It also includes ABX-10241 (ABX-PTH), which isa  fully human antibody therapeutic product candidate directed against parathyroid hormone for the treatment of a secondary hyper-para-thyroidism. Abgenix was established in 1996 and is headquartered in Fremont, California. It currently operates as a subsidiary of Amgen, Inc.

Immunex

Acquisition in 2002
Immunex Corporation develops, manufactures, and markets therapeutic products for the treatment of cancer, infectious diseases, and autoimmune disorders. It offers products, such as Enbrel that is used in the treatment of rheumatoid arthritis; Novantrone, which is used to treat acute nonlymphocytic leukemia and pain associated with prostate cancer; and Leukine for use in bone marrow transplant patients. The company has franchise operations. It has a strategic alliance with American Home Products. The company was founded in 1981 and is based in Seattle, Washington. As of July 15, 2002, Immunex Corporation was acquired by Amgen, Inc.

Oxford Nanopore Technologies

Venture Round in 2018
Oxford Nanopore Technologies Limited develops and commercializes nanopore-based electronic systems for analysis of single molecules. The company offers MinION, a portable device for molecular analysis based on nanopore technology and is adaptable for the analysis of DNA, RNA, proteins, and small molecules; MinIT, an analysis and device control accessory for nanopore DNA sequencing; PromethION, a tablet-sized benchtop instrument that provides real-time data streaming; GridION system for molecular sensing applications; 109 cDNA Kits for its real-time and scalable sequencing technology that provides high throughput whilst generating complete sequences of full-length cDNA strands; and Flongle, a paradigm of smaller on-demand DNA or RNA sequencing tests with the potential to transform a range of applications where insights are required at low cost. Its devices are used in scientific research, personalized medicine, crop science, and security and defense applications. The company sells its products online. Oxford Nanopore Technologies Limited was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies Limited in May 2008. The company was incorporated in 2005 and is based in Oxford, United Kingdom with additional offices in the United Kingdom, the United States, China, Japan, Germany, France, India, and Singapore.

Worldwide Rights to Otezla of Celgene Corporation

Merger/Acquisition in 2019
As of November 20, 2019, Worldwide Rights to Otezla of Celgene Corporation was acquired by Amgen Inc. Worldwide Rights to Otezla of Celgene Corporation comprises manufacturing of oral and non-biologic treatment for psoriasis and psoriatic arthritis medicine business. The asset is located in the United States.

Nuevolution AB (publ)

Acquisition in 2019
Nuevolution A/S operates as a biopharmaceutical company focused on developing drug treatments for human diseases within oncology and chronic inflammatory diseases. The company was founded in 2001 and is based in Copenhagen, Denmark. Nuevolution A/S operates as a subsidiary of Nuevolution AB (publ)

TeneoBio, Inc.

Acquisition in 2021
TeneoBio, Inc., a biotechnology company, develops biologics, such as human heavy chain antibodies (UniAbs) as therapeutics against cancer, autoimmunity, and infectious diseases. The company also develops products for the treatment of multiple myeloma, prostate cancer, immune disorders, and AIDS. The company develops antibodies including multiple myeloma bispecific, lymphoma trispecific, gp120 (HIV) bispecific, and immune checkpoint inhibitors. The company was founded in 2009 and is based in Menlo Park, California.

Bergamo

Acquisition in 2011
Develops drugs focused on serious diseases

Kinetix Pharmaceuticals

Acquisition in 2000
A company that specializes in discovering small molecules in the field of protein kinase inhibition.

Onyx Pharmaceuticals

Acquisition in 2013
Onyx Pharmaceuticals is a biopharmaceutical company committed to improving the lives of people with cancer. Their lead product is Nexavar (sorafenib), a novel, oral multiple kinase inhibitor that targets proteins involved in both tumor cell proliferation and angiogenesis.

Immatics US

Series E in 2017
Immatics US Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient, where they recognize and kill tumor cells. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company has a strategic cancer immunotherapy collaboration with Roche to research, develop, and commercialize various new cancer peptide antigen-based immunotherapies for targeting primarily gastric, prostate, and non-small cell lung cancer. Immatics US Inc. was founded in 2015 and is headquartered in Houston, Texas. Immatics US Inc. operates as a subsidiary of immatics biotechnologies GmbH.

BeiGene

Private Placement in 2019
BeiGene is a clinical-stage Biopharma company focused on discovering and developing innovative, best-in-class, targeted and immuno-oncology drugs that address severe unmet medical needs in a variety of cancer indications.

Rodeo Therapeutics Corp.

Acquisition in 2021
Rodeo Therapeutics Corp. is a drug development company. The company develops novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant. It develops drugs for tissue repair and regeneration. The company was incorporated in 2017 and is based in Seattle, Washington.

Nuevolution AB (publ)

Merger/Acquisition in 2019
Nuevolution A/S operates as a biopharmaceutical company focused on developing drug treatments for human diseases within oncology and chronic inflammatory diseases. The company was founded in 2001 and is based in Copenhagen, Denmark. Nuevolution A/S operates as a subsidiary of Nuevolution AB (publ)

Five Prime Therapeutics, Inc.

Acquisition in 2021
FivePrime is dis­cov­er­ing and devel­op­ing novel ther­a­peu­tic pro­teins and anti­bod­ies by sys­tem­at­i­cally screen­ing all rel­e­vant pro­teins in the human body to find the best pro­tein for treat­ment of a given clin­i­cal indi­ca­tion. FivePrime’s Pro­Screen Engine enables the rapid pro­duc­tion and screen­ing of all ther­a­peu­ti­cally rel­e­vant pro­teins in medically-​​focused assays at the high­est qual­ity stan­dards in the indus­try. This pow­er­ful approach is the polar oppo­site of the industry’s tra­di­tional “one pro­tein at a time”. The Pro­Screen Engine com­prises the defin­i­tive pro­tein col­lec­tion and screen­ing process for bio­log­ics dis­cov­ery and is unprece­dented in its effi­ciency, qual­ity and scale. In addi­tion to DBL Investors, investors include Domain Asso­ciates, Ver­sant Ven­tures, Kleiner Perkins Cau­field and Byers, Texas Pacific Group, Health­Cap and Advanced Tech­nol­ogy Ventures.

BeiGene

Post in 2019
BeiGene is a clinical-stage Biopharma company focused on discovering and developing innovative, best-in-class, targeted and immuno-oncology drugs that address severe unmet medical needs in a variety of cancer indications.

ARO-LPA Worldwide And Exclusive License of Arrowhead Pharmaceuticals, Inc.

Merger/Acquisition in 2016
As of September 30, 2016, ARO-LPA Worldwide And Exclusive License of Arrowhead Pharmaceuticals, Inc. was acquired by Amgen Inc.

eHealth Ventures

Corporate Round in 2016
eHealth Ventures is a consortium conceived to provide incubation services to promising early-stage healthcare technology companies in Israel. The Government of Israel offers a unique opportunity for leverage by providing significant financial incentives to incubators assisting technology start-ups capitalizing on Israel's extraordinarily rich talent pool. The next Tender is expected the second half of 2014. eHealth Ventures will apply for an eight-year license under the program. They are seeking qualified individual and institutional investors who would like to participate in this extraordinary, highly leveraged opportunity.

BioVex

Acquisition in 2011
BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.

Alantos Pharmaceuticals

Acquisition in 2007
Alantos Pharmaceuticals is a chemistry-driven biopharmaceutical company. It engages in the discovery and development of small molecule drugs for osteoarthritis, inflammation, and type II diabetes. Their products include Dipeptidyl and Peptidase IV inhibitor. The company offers various tissue remodeling pathways for rheumatoid arthritis, liver fibrosis, cardiovascular, chronic wound healing, and cancer. Alantos Pharmaceuticals was founded in 2002 and is based in Cambridge, Massachusetts.

Filgrastim and Pegfilgrastim

Acquisition in 2002
Filgrastim and pegfilgrastim are a supportive part of treatment for many patients receiving cancer chemotherapy. Some cancer drugs, in addition to attacking the cancer, destroy the patient's white blood cells, which are extremely important in fighting infection. Consequently, these patients are prone to developing severe, and even life-threatening, infections. Filgrastim and pegfilgrastim restore the number of white blood cells and thus improve their ability to kill infecting micro-organisms.

Unilife Corporation

Post in 2016
Unilife is a U.S-based medical device and technology company that designs, develops, manufactures and supplies innovative, differentiated delivery systems for injectable drugs and vaccines.

KAI Pharmaceuticals

Acquisition in 2012
KAI Pharmaceuticals is a drug discovery and development company with multiple, novel clinical-stage programs in the areas of cardiovascular disease, kidney disease and pain. KAI lead product candidate, KAI-9803, is currently in a Phase 2b study (PROTECTION AMI) designed to assess the effect of KAI-9803 on reducing myocardial injury in heart attack patients. KAI second core program, KAI-4169 for the treatment of secondary hyperparathyroidism (SHPT) in kidney disease patients, is expected to enter human clinical trials in 2010. KAI also has an ongoing pain program, KAI-1678, which is currently in Phase 2a testing.